Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7(1–2):4–13
Article CAS PubMed PubMed Central Google Scholar
Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E (2015) Molecular classification of breast carcinoma: from traditional, old-fashioned way to a new age, and a new way. J Breast Health 11(2):59–66
Article PubMed PubMed Central Google Scholar
Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312(3):146–151
Article CAS PubMed Google Scholar
Neal L, Sandhu NP, Hieken TJ, Glazebrook KN, Mac Bride MB, Dilaveri CA et al (2014) Diagnosis and management of benign, atypical, and indeterminate breast lesions detected on core needle biopsy. Mayo Clin Proc 89(4):536–547
Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K (2015) Atypical hyperplasia of the breast–risk assessment and management options. N Engl J Med 372(1):78–89
Article PubMed PubMed Central Google Scholar
Cuzick J, Sestak I, Thorat MA (2015) Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. Breast Edinb Scotl 24(Suppl 2):S51-55
Figueroa JD, Gierach GL, Duggan MA, Fan S, Pfeiffer RM, Wang Y et al (2021) Risk factors for breast cancer development by tumor characteristics among women with benign breast disease. Breast Cancer Res 23(1):34
Article CAS PubMed PubMed Central Google Scholar
Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y et al (2017) Role of tumor microenvironment in tumorigenesis. J Cancer 8(5):761–773
Article CAS PubMed PubMed Central Google Scholar
Soysal SD, Tzankov A, Muenst SE (2015) Role of the tumor microenvironment in breast cancer. Pathobiology 82(3–4):142–152
Article CAS PubMed Google Scholar
Mittal S, Brown NJ, Holen I (2018) The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Rev Mol Diagn 18(3):227–243
Article CAS PubMed Google Scholar
Mehraj U, Dar AH, Wani NA, Mir MA (2021) Tumor microenvironment promotes breast cancer chemoresistance. Cancer Chemother Pharmacol 87(2):147–158
Folgueira MAAK, Maistro S, Katayama MLH, Roela RA, Mundim FGL, Nanogaki S et al (2013) Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series. Biosci Rep 33(6):e00085
Article PubMed PubMed Central Google Scholar
Knower KC, Chand AL, Eriksson N, Takagi K, Miki Y, Sasano H et al (2013) Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Res Treat 142(1):211–223
Article CAS PubMed Google Scholar
Cid S, Eiro N, Fernández B, Sánchez R, Andicoechea A, Fernández-Muñiz PI et al (2018) Prognostic influence of tumor stroma on breast cancer subtypes. Clin Breast Cancer 18(1):e123–e133
Article CAS PubMed Google Scholar
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol Off J Am Soc Clin Oncol 38(12):1346–1366
Shao ZM, Nguyen M, Barsky SH (2000) Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19(38):4337–4345
Article CAS PubMed Google Scholar
Hilton HN, Clarke CL, Graham JD (2018) Estrogen and progesterone signalling in the normal breast and its implications for cancer development. Mol Cell Endocrinol 5(466):2–14
Lamb CA, Fabris VT, Jacobsen BM, Molinolo A, Lanari C (2018) Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer. Endocr Relat Cancer 25(12):R605–R624
Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB et al (2004) Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10(8):2751–2760
Article CAS PubMed Google Scholar
Calhoun BC, Mosteller B, Warren D, Smith M, Jordi Rowe J, Lanigan CP et al (2018) Analytical and clinical performance of progesterone receptor antibodies in breast cancer. Ann Diagn Pathol 1(35):21–26
Booth ME, Hanby AM, Speirs V (2014) Steroid hormone receptor expression in breast cancer stroma. Breast Cancer Res Treat 143(3):605–607
Creighton CJ, Osborne CK, van de Vijver MJ, Foekens JA, Klijn J, Horlings HM et al (2009) Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 114(2):287–299
Article CAS PubMed Google Scholar
Prat A, Cheang MCU, Martín M, Parker JS, Carrasco E, Caballero R et al (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol 31(2):203–209
Article CAS PubMed Google Scholar
O’Neill JS, Miller WR (1987) Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases. Br J Cancer 56(5):601–604
Article PubMed PubMed Central Google Scholar
Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, Vihko R et al (1996) Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 81(11):4042–4046
Santen RJ, Santner SJ, Pauley RJ, Tait L, Kaseta J, Demers LM et al (1997) Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J Steroid Biochem Mol Biol 61(3–6):267–271
Article CAS PubMed Google Scholar
Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA (2012) TNBCtype: a subtyping tool for triple-negative breast cancer. Cancer Informatics 11:147–153
Article PubMed PubMed Central Google Scholar
Lehmann BD, Pientenpol JA (2014) Identification and use of biomarkers in treatment strategies for triple negative breast cancer subtypes. J Pathol 232(2):142–150
Article PubMed PubMed Central Google Scholar
Li Q, Eklund AC, Juul N, Haibe-Kains B, Workman CT, Richardson AL et al (2010) Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status. PLoS ONE 5(12):e15031
Article CAS PubMed PubMed Central Google Scholar
Troxell ML, Long T, Hornick JL, Ambaye AB, Jensen KC (2017) Comparison of estrogen and progesterone receptor antibody reagents using proficiency testing data. Arch Pathol Lab Med 141(10):1402–1412
Article CAS PubMed Google Scholar
Khoury T (2018) Delay to formalin fixation (Cold Ischemia Time) effect on breast cancer molecules. Am J Clin Pathol 149(4):275–292
留言 (0)